Phase Ib study of anlotinib in combination with anti‐PD‐L1 antibody ( TQB2450 ) in patients with advanced acral melanoma
Journal of the European Academy of Dermatology and Venereology · 2024-01 · 38 (1) · 93-101
DOI: 10.1111/jdv.19467 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 04.09.2023. Verfasst von Yu Du und 18 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking Univers…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Immune Checkpoint Inhibitors, Indoles, Melanoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Chia Tai TianQing Pharmaceutical Group Co., Ltd.
Abstract (Originalsprache)
Background
Acral melanoma, the most common subtype of melanoma in Asians, is often diagnosed at an advanced stage and responds poorly to current programmed cell death protein 1 (PD‐1) inhibitors.
Objectives
To evaluate the safety and efficacy of TQB2450 and anlotinib in patients with advanced acral melanoma in a phase Ib study (NCT03991975).
Methods
Patients received TQB2450 (1200 mg every 3 weeks) and anlotinib (10 mg or 12 mg once daily, 2‐week on/1‐week off) in the dose‐escalation and dose‐expansion phases. The primary endpoints were dose‐limiting toxicity (DLT), maximum tolerated dose (MTD) and objective response rate (ORR).
Results
Nineteen patients were enrolled between June 2019 and June 2022. The majority of patients (16 of 19 patients) received anlotinib and TQB2450 as first‐line treatment. No DLTs were observed, and MTD was not reached. Eighteen (94.7%) out of 19 patients experienced treatment‐related adverse events (TRAEs), but most were grade 1 or 2. Grade 3 or greater TRAEs occurred in seven patients (36.8%). The ORR was 26.3% (two complete responses and three partial responses). The disease control rate was 73.7%. The median duration of response was 30.3 months [95% confidence interval (CI): 5.8–NA]. The median progression‐free survival (PFS) was 5.5 months (95% CI: 2.8–NA), and median overall survival was 20.3 months (95% CI: 14.8–NA). Whole‐exome sequencing suggested that acquired drug resistance might be attributed to activation of the MAPK signalling pathway and transformation to an immunosuppressive tumour environment.
Conclusions
TQB2450 combined with anlotinib showed favourable tolerance and promising anti‐tumour activity with a prolonged PFS compared with anti‐PD1 monotherapy in patients with advanced acral melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China.
- Department of Medical Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, China.
Förderung
- Chia Tai TianQing Pharmaceutical Group Co., Ltd
Zitieren
APA
Du, Y., Dai, J., Mao, L., Wei, X., Bai, X., Chen, L., Lin, J., Chi, Z., Cui, C., Sheng, X., Lian, B., Tang, B., Wang, X., Yan, X., Li, S., Zhou, L., Guo, J., Chen, Y., & Si, L. (2024). Phase Ib study of anlotinib in combination with anti‐PD‐L1 antibody ( TQB2450 ) in patients with advanced acral melanoma. Journal of the European Academy of Dermatology and Venereology, 38(1), 93-101. https://doi.org/10.1111/jdv.19467
Vancouver
Du Y, Dai J, Mao L, Wei X, Bai X, Chen L, et al. Phase Ib study of anlotinib in combination with anti‐PD‐L1 antibody ( TQB2450 ) in patients with advanced acral melanoma. Journal of the European Academy of Dermatology and Venereology. 2024;38(1):93-101. doi:10.1111/jdv.19467
BibTeX
@article{Du2024,
author = {Du, Yu and Dai, Jie and Mao, Lili and Wei, Xiaoting and Bai, Xue and Chen, Ling and Lin, Jing and Chi, Zhihong and Cui, Chuanliang and Sheng, Xinan and Lian, Bin and Tang, Bixia and Wang, Xuan and Yan, Xieqiao and Li, Siming and Zhou, Li and Guo, Jun and Chen, Yu and Si, Lu},
title = {Phase Ib study of anlotinib in combination with anti‐PD‐L1 antibody ( TQB2450 ) in patients with advanced acral melanoma},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
volume = {38},
number = {1},
pages = {93--101},
doi = {10.1111/jdv.19467}
}
EUVIMED